SG11201407803TA - Nmr measurements of glyca - Google Patents

Nmr measurements of glyca

Info

Publication number
SG11201407803TA
SG11201407803TA SG11201407803TA SG11201407803TA SG11201407803TA SG 11201407803T A SG11201407803T A SG 11201407803TA SG 11201407803T A SG11201407803T A SG 11201407803TA SG 11201407803T A SG11201407803T A SG 11201407803TA SG 11201407803T A SG11201407803T A SG 11201407803TA
Authority
SG
Singapore
Prior art keywords
lllll
international
glyca
north carolina
llll
Prior art date
Application number
SG11201407803TA
Other languages
English (en)
Inventor
James D Otvos
Irina Y Shalaurova
Dennis W Bennett
Justyna E Wolak-Dinsmore
Original Assignee
Liposcience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposcience Inc filed Critical Liposcience Inc
Publication of SG11201407803TA publication Critical patent/SG11201407803TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0044—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/4625—Processing of acquired signals, e.g. elimination of phase errors, baseline fitting, chemometric analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2576/00—Medical imaging apparatus involving image processing or analysis
    • A61B2576/02—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part
    • A61B2576/023—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part for the heart
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Signal Processing (AREA)
  • Radiology & Medical Imaging (AREA)
  • Artificial Intelligence (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Food Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Cardiology (AREA)
SG11201407803TA 2012-06-08 2013-05-30 Nmr measurements of glyca SG11201407803TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261657315P 2012-06-08 2012-06-08
US201261711471P 2012-10-09 2012-10-09
US201261739305P 2012-12-19 2012-12-19
US13/830,199 US9470771B2 (en) 2012-06-08 2013-03-14 NMR measurements of NMR biomarker GlycA
PCT/US2013/043343 WO2013184483A1 (fr) 2012-06-08 2013-05-30 Mesures de rmn de glyca

Publications (1)

Publication Number Publication Date
SG11201407803TA true SG11201407803TA (en) 2014-12-30

Family

ID=49712504

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407803TA SG11201407803TA (en) 2012-06-08 2013-05-30 Nmr measurements of glyca

Country Status (9)

Country Link
US (3) US9470771B2 (fr)
EP (2) EP3839544A1 (fr)
JP (1) JP6177899B2 (fr)
CN (1) CN104508471B (fr)
AU (1) AU2013272014B2 (fr)
CA (2) CA3146947A1 (fr)
HK (1) HK1207156A1 (fr)
SG (1) SG11201407803TA (fr)
WO (1) WO2013184483A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9076342B2 (en) 2008-02-19 2015-07-07 Architecture Technology Corporation Automated execution and evaluation of network-based training exercises
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US20140358451A1 (en) * 2013-06-04 2014-12-04 Arizona Board Of Regents On Behalf Of Arizona State University Fractional Abundance Estimation from Electrospray Ionization Time-of-Flight Mass Spectrum
CN106415276B (zh) * 2013-11-27 2018-10-16 威尔吉利健康研究所 用于表征脂蛋白的方法
WO2015103553A1 (fr) * 2014-01-06 2015-07-09 Liposcience, Inc. Paramètres de risque à marqueur multiple prédictifs de conversion au diabète
WO2016040859A1 (fr) 2014-09-11 2016-03-17 Liposcience Inc. Évaluations de risque cardiovasculaire à l'aide d'un paramètre de risque qui comporte un paramètre d'interaction de hdl et d'un marqueur biologique inflammatoire
WO2016065633A1 (fr) * 2014-10-31 2016-05-06 华为技术有限公司 Circuit d'ajustement de courbe, dispositif de prédistorsion analogique et émetteur de signal radiofréquence
US10083624B2 (en) 2015-07-28 2018-09-25 Architecture Technology Corporation Real-time monitoring of network-based training exercises
US10803766B1 (en) 2015-07-28 2020-10-13 Architecture Technology Corporation Modular training of network-based training exercises
EP3258285B1 (fr) * 2016-06-14 2020-10-21 Bruker BioSpin GmbH Procédé de prédiction de valeurs de deplacement chimique de systemes de spin rmn dans un échantillon d'une classe de fluides, en particulier dans un échantillon d'un fluide biologique
DE102016224691A1 (de) * 2016-12-12 2018-06-14 Numares Ag Verfahren zur Analyse eines NMR-Spektrums einer lipoproteinhaltigen Probe
FI20177098A1 (fi) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
EP3652743A1 (fr) * 2017-09-07 2020-05-20 Liposcience, Inc. Évaluations d'indice de vulnérabilité métabolique à paramètres multiples
CN107796946B (zh) * 2017-10-20 2019-10-25 中国医学科学院基础医学研究所 尿液中冠心病的蛋白标志物及其用途
US20200367795A1 (en) * 2018-01-18 2020-11-26 New York University System and method for blood glucose monitoring using magnetic resonance spectroscopy
CN109805898B (zh) * 2019-03-22 2024-04-05 中国科学院重庆绿色智能技术研究院 基于注意力机制时序卷积网络算法的危重症死亡预测方法
US11887505B1 (en) 2019-04-24 2024-01-30 Architecture Technology Corporation System for deploying and monitoring network-based training exercises
US20240044826A1 (en) 2022-08-05 2024-02-08 Liposcience, Inc. Metabolic vulnerability analyzed by nmr
DE102023110285B3 (de) 2023-04-21 2024-05-08 Universität zu Lübeck, Körperschaft des öffentlichen Rechts Nmr-messung von glykoproteinen

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529710A (en) 1981-06-12 1985-07-16 The United States Of America As Represented By The United States Department Of Energy Method of using a nuclear magnetic resonance spectroscopy standard
JPH0698036B2 (ja) 1986-10-20 1994-12-07 小野薬品工業株式会社 アミノ酸の選択的定量法
US4933844A (en) 1988-09-26 1990-06-12 Otvos James D Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer
WO2000051054A1 (fr) 1999-02-26 2000-08-31 Lipomed, Inc. Procedes, systemes et produits pour programmes informatiques, pour l'analyse et la presentation de resultats d'evaluation des risques bases sur la concentration mesureee par resonance magnetique nucleaire des lipoproteines dans le sang
US6653140B2 (en) * 1999-02-26 2003-11-25 Liposcience, Inc. Methods for providing personalized lipoprotein-based risk assessments
WO2000065366A1 (fr) 1999-04-22 2000-11-02 Lipomed, Inc. Methode utilisant l'irm pour determiner le risque de developper un diabete non insulino-dependant
CA2331116A1 (fr) 2001-01-15 2002-07-15 Chenomx, Inc. Identification et quantification de composes aqueux--technique et procede utilisant un systeme automatise de mesure a resonance magnetique nucleaire
US6617167B2 (en) 2001-08-01 2003-09-09 Liposcience, Inc. Method of determining presence and concentration of lipoprotein X in blood plasma and serum
AU2003232406A1 (en) 2002-06-14 2003-12-31 Pfizer Inc. Metabolic phenotyping
AU2003285926A1 (en) 2002-10-25 2004-05-25 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
WO2004085996A2 (fr) 2003-03-20 2004-10-07 Albert Einstein College Of Medicine Of Yeshiva University Biomarqueurs permettant de determiner la longevite et la maladie et utilisations
AU2004286629A1 (en) 2003-10-23 2005-05-12 Liposcience, Inc. Methods, systems and computer programs for assessing CHD risk using mathematical models that consider in vivo concentration gradients of LDL particle subclasses of discrete size
EP2189802B1 (fr) 2004-04-01 2014-05-14 Liposcience, Inc. Analyseurs RMN cliniques et méthodes , systèmes, modules et produits de programmes d'ordinateur pour l'évaluation clinique de bio-échantillons
WO2006057081A1 (fr) 2004-11-24 2006-06-01 Mitsuyo Okazaki Methode d'analyse de lipoproteines
JP5006524B2 (ja) 2005-05-13 2012-08-22 株式会社日立製作所 緩和時間特定のためのｎｍｒ装置の信号処理方法
JP4358814B2 (ja) 2005-11-09 2009-11-04 花王株式会社 試料の解析方法
DE602007011592D1 (de) 2006-03-24 2011-02-10 Metanomics Gmbh MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II
WO2007133593A2 (fr) 2006-05-10 2007-11-22 Liposcience, Inc. Procédés, systèmes et programmes informatiques permettant l'évaluation de risque de maladie coronarienne mettant en oeuvre des mesures de nombre de particules de lipoprotéine haute densité
WO2008137075A2 (fr) 2007-05-02 2008-11-13 President And Fellows Of Harvard College Compositions et procédés pour le traitement de troubles métaboliques et d'une inflammation
US7923257B2 (en) 2007-05-04 2011-04-12 Perkinelmer Health Sciences, Inc. Detecting isomers using differential derivatization mass spectrometry
EP2019311A1 (fr) 2007-07-23 2009-01-28 F.Hoffmann-La Roche Ag Procédé de détection d'une substance cible par résonance magnétique nucléaire
US20110311650A1 (en) 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
US8386187B2 (en) 2008-10-20 2013-02-26 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
WO2010114897A1 (fr) 2009-03-31 2010-10-07 Metabolon, Inc. Biomarqueurs liés à la résistance à l'insuline et leurs procédés d'utilisation
US8741788B2 (en) 2009-08-06 2014-06-03 Applied Materials, Inc. Formation of silicon oxide using non-carbon flowable CVD processes
US7935643B2 (en) 2009-08-06 2011-05-03 Applied Materials, Inc. Stress management for tensile films
US8449942B2 (en) 2009-11-12 2013-05-28 Applied Materials, Inc. Methods of curing non-carbon flowable CVD films
US20110136241A1 (en) 2009-12-08 2011-06-09 Stephen Naylor Type ii diabetes molecular bioprofile and method and system of using the same
KR101528832B1 (ko) 2010-01-06 2015-06-15 어플라이드 머티어리얼스, 인코포레이티드 유동성 유전체 층의 형성 방법
US10267800B2 (en) 2010-05-21 2019-04-23 The Governors Of The University Of Alberta Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
WO2014059025A1 (fr) 2012-10-09 2014-04-17 Liposcience, Inc. Quantification par nmr d'acides aminés à chaîne ramifiée

Also Published As

Publication number Publication date
US11692995B2 (en) 2023-07-04
CN104508471B (zh) 2017-09-19
HK1207156A1 (en) 2016-01-22
US20210080452A1 (en) 2021-03-18
CA3146947A1 (fr) 2013-12-12
AU2013272014B2 (en) 2017-05-25
US20170003269A1 (en) 2017-01-05
US20130328561A1 (en) 2013-12-12
EP3839544A1 (fr) 2021-06-23
EP2859339A1 (fr) 2015-04-15
JP2015522806A (ja) 2015-08-06
EP2859339A4 (fr) 2016-08-03
CA2874550C (fr) 2022-04-19
JP6177899B2 (ja) 2017-08-09
US10852293B2 (en) 2020-12-01
US9470771B2 (en) 2016-10-18
WO2013184483A1 (fr) 2013-12-12
AU2013272014A1 (en) 2014-12-18
CA2874550A1 (fr) 2013-12-12
CN104508471A (zh) 2015-04-08
EP2859339B1 (fr) 2020-10-28

Similar Documents

Publication Publication Date Title
SG11201407803TA (en) Nmr measurements of glyca
SG11201408002TA (en) Multi-parameter diabetes risk evaluations
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201408793XA (en) Methods related to real-time cancer diagnostics at endoscopy utilizing fiber-optic raman spectroscopy
SG11201407898WA (en) Electrode testing apparatus
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201809294RA (en) Systems and methods for sensor data analysis through machine learning
SG11201408261UA (en) Syringe
SG11201408069XA (en) Hair styling device
SG11201804711RA (en) Compounds and methods for kinase modulation, and indications therefor
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201806442YA (en) Systems and methods for calibrating an optical distance sensor
SG11201407610WA (en) Cd33 antibodies and use of same to treat cancer
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201407747QA (en) A method and apparatus for facilitating the management of health and security
SG11201408491SA (en) Analogs of glucagon exhibiting gip receptor activity
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201408539UA (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG11201407662WA (en) Process for the preparation of treprostinil and derivatives thereof
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions